V3
李洪峰 声望 7
环境
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
作者:, Georgina V. Long
摘要:Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint inhibitors has revolutionised management and improved outcomes for patients with advanced stage disease. However, acquired resistance to MAPK inhibitor therapy develops in the majority of patients at approximately 12 months and multiple mechanisms lead to resistance. Understanding the mechanisms of resistance is therefore critical for the development of more effective therapeutic strategies in BRAF-mutant melanoma. Recently, several distinct mechanisms of resistance to BRAF-inhibition have been proposed based on data obtained in experimental melanoma cell models and small series of human tumour samples. These include reactivation of the MAPK pathway resulting in continued extracellular signal-regulated kinase activation and activation of parallel signalling pathways including the PI3K-mTOR (phosphoinositide 3-kinase–mammalian target of rapamycin) pathway. Alterations in how the cells of the immune system respond to melanoma cells treated with targeted therapy may also influence response and progression. In this review, we discuss these mechanisms and identify potential therapeutic strategies to overcome resistance which, in turn, will lead to improved outcomes for patients with metastatic melanoma.
关键词:
论文方向:
发表期刊:European Journal of Cancer Volume 62
发表时间:Sun Jul 31 00:00:00 CST 2016
数字识别码:10.1016/j.ejca.2016.04.005
是否作者本人:

版权及免责声明:

本网站所有论文文件均系用户自行上传或提供,本网站对其内容准确性及合法性概不负责,亦不承担任何法律责任。论文版权归原作者及原出处所有。

如您发现网站其他用户上传的论文有侵犯您的姓名权、隐私权、著作权或其他合法权益现象的,请及时与本网站联系并附加相关权利证明文件,以便本网站及时作出处理,维护您的合法权益。

本网站拥有对此声明的最终解释权。

全部评论 ( 0 )

发评论
5.0/10分

0人评分